Ahead of the annual general meeting, the Nomination Committee originally proposed that the Board of Directors shall consist of six members, that Berndt Axelsson, Mats Johansson, Orest Lastow and Carl Lindgren are re-elected as ordinary Board members, that Erik Westerlund and Andreas Engström are elected as new ordinary Board members, and that Carl Lindgren is re-elected as Chairman of the Board. Since the Nomination Committee has been informed that FSG has participated in the rights issue that has just been completed and that FSG, after final registration of the rights issue, will hold approximately 15.5 per cent[1] of the shares and votes in Iconovo, the Nomination Committee has, after discussions with FSG, decided to revise its proposal by proposing, in addition to the persons previously proposed, that Christer Fåhraeus is elected as a new member of the Board of Directors.

Accordingly, the Nomination Committee's revised proposal is that the Board of Directors shall consist of seven members, that Berndt Axelsson, Mats Johansson, Orest Lastow and Carl Lindgren are re-elected as ordinary Board members, that Erik Westerlund, Andreas Engström and Christer Fåhraeus are elected as new ordinary Board members, and that Carl Lindgren is re-elected as Chairman of the Board of Directors.

Christer Fåhraeus has announced that he declines remuneration for his board duties. The Nomination Committee's proposal regarding Board remuneration in general remains unchanged in relation to the original proposal.

"We are very pleased to welcome Christer as a proposed Board member and FSG as the second largest shareholder in the company. Christer has a solid experience and expertise in building successful companies in Life Science that we will benefit greatly from on the Board. Furthermore, we see FSG's investment in the company as an acknowledgement of the commercial potential and opportunity that exists in Iconovo.", says Mats Johansson, Chairman of the Nomination Committee.

Christer Fåhraeus, born 1965, holds a Bachelor of Medicine and a PhD in Neurophysiology from the Faculty of Medicine at Lund University, a Master of Science in Medical Engineering from the University of California San Diego (USA), and the equivalent of five years of full-time studies in mathematics and physics at Lund University and LTH (engineering physics). He is a graduate of the Swedish Armed Forces Interpreter School and holds an honorary doctorate in technology from Lund University. Christer Fåhraeus has 30 years of experience as CEO and board member in listed and unlisted companies in Life Science and Tech and is the founder of companies such as CellaVision AB, FlatFrog Laboratories AB, Anoto Group AB, Precise Biometrics AB, EQL Pharma AB and Fåhraeus Startup and Growth AB.

Christer Fåhraeus' other ongoing assignments include: Chairman of the Board of EQL Pharma AB, ApoEco Sverige AB, Fåhraeus Startup & Growth AB and FSG Fund II AB, Board member of CellaVision AB, Fåhraeus Institute AB, Fårö Capital AB, Wranne Fåhraeus Design AB, Theope Seed Capital AB, FlatFrog Laboratories AB, OssDsign AB, Oncorena AB, Oncorena Holding AB, EQL Pharma Int AB, Smältan Invest AB, Checkin Group AB, Bionamic AB and Melius Pharma AB and Deputy Board member of Rapidus Media AB and CJ Scandinavian Seaview Consulting AB.

Christer Fåhraeus does not own any shares in Iconovo.

Christer Fåhraeus is considered to be independent in relation to the company and its management as well as in relation to its major shareholders.

For further information, please contact:

Mats Johansson, Chairman of the Nomination Committee
Tel: +46 70 646 30 35
E-mail: mats.johansson@abraxasholding.com

[1] Allotment of shares exceeding 9.99 per cent of the total number of votes in Iconovo is subject to FSG's investment being approved or left without action by the Swedish Inspectorate for Strategic Products (the "ISP") under the Screening of Foreign Direct Investments Act (2023:560). FSG has submitted an application to the ISP and expects the investment to be finalised in June 2025.